Physician profile
Frederick Lee Flynt
NPI 1235356247
$9,357.19
in general payments reported to CMS, 2019-2025
73 companies · $1,795 in 2025
The $1,795 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $265 · 2020: $423 · 2021: $902 · 2022: $1,605 · 2023: $2,449 · 2024: $1,918 · 2025: $1,795.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,970 · Education: $193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,969.57 |
| Education | $193.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $927.87 | 2019-2025 | |
| Janssen Biotech, INC. | $614.94 | 2019-2025 | Darzalex, Imbruvica, Talvey |
| Pharmacyclics LLC, An Abbvie Company | $589.09 | 2021-2023 | Imbruvica, Epkinly |
| Merck Sharp & Dohme LLC | $583.25 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Daiichi Sankyo INC. | $321.93 | 2023-2025 | Enhertu, Datroway |
| Amgen INC. | $320.71 | 2020-2023 | Lumakras, Kyprolis, Nplate |
| Abbvie INC. | $299.87 | 2022-2025 | |
| Gilead Sciences, INC. | $298.84 | 2019-2025 | Trodelvy |
| Genzyme Corporation | $280.90 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $264.73 | 2019-2025 | Fruzaqla, Ninlaro, Iclusig |
| Pfizer INC. | $257.91 | 2019-2025 | |
| Glaxosmithkline, LLC. | $243.91 | 2021-2025 | Shingrix, Ojjaara, Zejula |
| Stemline Therapeutics INC. | $238.40 | 2023-2025 | Orserdu |
| Incyte Corporation | $224.11 | 2020-2025 | Monjuvi, Zynyz, Jakafi |
| Genentech USA, INC. | $220.35 | 2021-2025 | Lunsumio, Columvi, Venclexta |
Show all 72 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $220.13 | 2019-2025 | Lynparza, Enhertu |
| Seagen INC. | $219.64 | 2019-2023 | Adcetris, Tukysa, Padcev |
| Exelixis INC. | $199.47 | 2021-2025 | Cabometyx |
| Celgene Corporation | $184.46 | 2019-2024 | Reblozyl, Pomalyst |
| Array Biopharma INC | $178.98 | 2021-2025 | Braftovi, Mektovi, Lorbrena |
| Bayer Healthcare Pharmaceuticals INC. | $153.59 | 2019-2025 | |
| Lilly USA, LLC | $146.30 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| Sirtex Medical INC | $138.35 | 2023 | Sir-Spheres Microspheres |
| Eisai INC. | $130.21 | 2020-2023 | |
| Karyopharm Therapeutics INC. | $117.57 | 2020-2024 | Xpovio |
| E.R. Squibb & Sons, L.L.C. | $114.77 | 2022-2024 | Opdualag |
| Emd Serono, INC. | $112.74 | 2019-2025 | Bavencio |
| Regeneron Healthcare Solutions, INC. | $110.10 | 2022-2025 | Libtayo |
| Astellas Pharma US INC | $100.46 | 2022-2025 | Xtandi, Padcev, Xospata |
| Jazz Pharmaceuticals INC. | $97.09 | 2023-2024 | |
| Beigene USA, INC. | $89.39 | 2022-2025 | Brukinsa, Tevimbra |
| Acrotech Biopharma INC. | $80.72 | 2021-2024 | Beleodaq |
| Tersera Therapeutics LLC | $77.03 | 2022-2023 | Zoladex |
| Pharmaessentia USA Corporation | $74.58 | 2023-2025 | Besremi |
| Rigel Pharmaceuticals, INC. | $59.03 | 2022-2024 | Rezlidhia, Tavalisse |
| Taiho Oncology, INC. | $58.20 | 2022-2023 | |
| Epizyme, INC. | $55.66 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $53.57 | 2022-2025 | Onivyde |
| Adaptive Biotechnologies Corporation | $50.06 | 2024-2025 | Clonoseq |
| Legend Biotech USA INC. | $43.06 | 2025 | Carvykti |
| Beone Medicines USA, INC. | $43.06 | 2025 | Brukinsa, Tevimbra |
| Mirati Therapeutics, INC. | $41.18 | 2024 | Krazati |
| Springworks Therapeutics, INC. | $41.04 | 2024-2025 | Ogsiveo |
| Sobi, INC | $40.46 | 2024-2025 | |
| Kite Pharma, INC. | $40.43 | 2021-2023 | |
| Recordati_rare_diseases_inc. | $39.41 | 2025 | Enjaymo |
| Spectrum Pharmaceuticals INC. | $36.34 | 2025 | Rolvedon |
| Adc Therapeutics America, INC. | $35.52 | 2022-2025 | |
| Novo Nordisk INC | $34.66 | 2020 | |
| Servier Pharmaceuticals LLC | $33.56 | 2023-2024 | |
| Aveo Pharmaceuticals, INC. | $30.19 | 2022 | |
| Geron Corporation | $28.36 | 2025 | Rytelo |
| Delcath Systems | $26.46 | 2025 | Hepzato Kit |
| Tempus Ai, INC | $25.96 | 2025 | Xt Cdx |
| Sumitomo Pharma America, INC. | $24.56 | 2023 | Orgovyx |
| Puma Biotechnology, INC. | $23.90 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $20.87 | 2020 | |
| Sun Pharmaceutical Industries INC. | $19.99 | 2024 | |
| Organon LLC | $19.65 | 2021 | |
| Blueprint Medicines Corporation | $19.16 | 2023 | Ayvakit |
| Cti Biopharma Corp. | $18.97 | 2023 | Vonjo |
| Foundation Medicine, INC. | $17.80 | 2022 | |
| Deciphera Pharmaceuticals INC. | $17.36 | 2023 | Qinlock |
| Acceleron Pharma, INC. | $15.92 | 2021 | |
| Kyowa Kirin, INC. | $15.46 | 2024 | Poteligeo |
| Accord Healthcare, INC. | $15.20 | 2025 | |
| Janssen Pharmaceuticals, INC | $14.70 | 2025 | Erleada |
| Octapharma USA, INC. | $13.66 | 2025 | Octagam Immune Globulin (Human) |
| Dova Pharmaceuticals | $13.52 | 2020 | |
| Horizon Therapeutics Plc | $13.33 | 2021 | |
| Coherus Oncology, INC. | $12.84 | 2021 | |
| Agios Pharmaceuticals, INC. | $11.70 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Flynt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.